Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optigenex expands Promethean partnership

This article was originally published in The Tan Sheet

Executive Summary

Promethean Corp. plans to expand its products into new markets under a renewed alliance with Optigenex Inc., which supplies the AC-11 ingredient to Promethean. The expanded licensing rights agreement announced Aug. 17 allows Promethean subsidiary Ceres Living to promote its skin care products and AIO Premium Cellular Health dietary supplements containing AC-11 worldwide, except in Japan and Turkey. Optigenex CEO Daniel Zwiren said the firms wanted "to expand our interactions into something more akin to a product development and marketing partnership than a supplier-customer relationship." The ingredient supplier claims AC-11 is the only product to repair DNA at the cellular level both systemically and topically (1"The Tan Sheet" April 5, 2010)

You may also be interested in...

After Quiet Start, Optigenex Looks To Make Noise As Anti-Aging Brand

Optigenex got started in business largely as a silent supplier for beauty care giant Estee Lauder, but the firm has transitioned to making itself known as a developer of skin care and supplement ingredients that stimulate DNA repair as anti-aging agents

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts